ConductScience.org, home

Paper39300079

Current status and research directions in acute myeloid leukemia.

Kantarjian H and 10 others. Blood Cancer J, 2024. Cited by 115 papers, by iCite.

Cite this record

ConductScience Library. Current status and research directions in acute myeloid leukemia. Papers, record 39300079. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39300079

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Current status and research directions in acute myeloid leukemia.
PubMed
Journal
Blood Cancer J
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
115
iCite
Relative citation ratio, by iCite
15.82, provisional
iCite
Revised in PubMed
2026-11-02
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
Humans
Molecular Targeted Therapy
Antineoplastic Agents

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30CA016672NIH

Source NIH RePORTER

Download CSV of grants

References181

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131088841Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.Cancer Discov2019https://conductscience.org/library/papers/31088841PubMed
224346116Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.Cancer Discov2014https://conductscience.org/library/papers/24346116PubMed
337379495Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.J Clin Oncol2023https://conductscience.org/library/papers/37379495PubMed
416728980Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia.Leukemia2006https://conductscience.org/library/papers/16728980PubMed
525809968Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.Cancer2015https://conductscience.org/library/papers/25809968PubMed
635772432Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia.Lancet Haematol2022https://conductscience.org/library/papers/35772432PubMed
715187030Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.Blood2004https://conductscience.org/library/papers/15187030PubMed
835797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022https://conductscience.org/library/papers/35797463PubMed
937187198Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.Lancet Haematol2023https://conductscience.org/library/papers/37187198PubMed
1034043428Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol2021https://conductscience.org/library/papers/34043428PubMed
1133681815Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.Blood Cancer Discov2021https://conductscience.org/library/papers/33681815PubMed
1233374216Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden.Cancers (Basel)2020https://conductscience.org/library/papers/33374216PubMed
1337003279Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.Lancet Haematol2023https://conductscience.org/library/papers/37003279PubMed
1438583455
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Lancet Haematol2024https://conductscience.org/library/papers/38583455PubMed
1512393590All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.Blood2002https://conductscience.org/library/papers/12393590PubMed
1636892949Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.Cancer2023https://conductscience.org/library/papers/36892949PubMed
1729601269Molecular Minimal Residual Disease in Acute Myeloid Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29601269PubMed
1825833957A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.Blood2015https://conductscience.org/library/papers/25833957PubMed
1932561839The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.Leukemia2021https://conductscience.org/library/papers/32561839PubMed
2038113472Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.Blood Adv2024https://conductscience.org/library/papers/38113472PubMed

See all 181 referencesDownload CSV of references

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 115 citations.

PMIDTitleJournalYearIn PapersSource
42957740Deep learning predicts IDH1 mutation status in acute myeloid leukemia from bone marrow smears.NPJ Precis Oncol2026https://conductscience.org/library/papers/42957740PubMed
42882927Clinical and Treatment-Related Factors Associated with Neutrophil Recovery After Bloodstream Infection in Acute Leukemia: A Competing-Risk Analysis.Cancers (Basel)2026https://conductscience.org/library/papers/42882927PubMed
42882877Developing a Dual-Targeting CD33/CD70 CAR T-Cell Strategy Against Acute Myeloid Leukemia to Overcome Tumor Heterogeneity.Cancers (Basel)2026https://conductscience.org/library/papers/42882877PubMed
42864652CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML.Genome Med2026https://conductscience.org/library/papers/42864652PubMed
42801107Liposomal-Mitoxantrone Overcomes Acquired Resistance and Enhances Venetoclax Synergy in AML-Mechanistic Insights and Preliminary Clinical Evidence.Int J Nanomedicine2026https://conductscience.org/library/papers/42801107PubMed
42724439Association between the systemic immune-inflammation index and overall survival in patients with leukemia: a multicenter cohort study.Transl Cancer Res2026https://conductscience.org/library/papers/42724439PubMed
42722966Treatment Preferences for Acute Myeloid Leukemia in Harbin, China: A Discrete Choice Experiment Among Patients, Caregivers, and Hematologists.Patient2026https://conductscience.org/library/papers/42722966PubMed
42690491High expression of CD74 is associated with poor prognosis and tumor immune infiltration in Acute Myeloid Leukemia.Discov Oncol2026https://conductscience.org/library/papers/42690491PubMed
42680202Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy.J Immunother Cancer2026https://conductscience.org/library/papers/42680202PubMed
42527666Adaptor-mediated rewiring of FLT3 signaling engages p38 MAPK to sustain gilteritinib resistance in acute myeloid leukemia.Leukemia2026https://conductscience.org/library/papers/42527666PubMed
42452347Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.J Clin Med2026https://conductscience.org/library/papers/42452347PubMed
42368576Lactate metabolism and epigenetic reprogramming drive c-KIT hyperactivation to mediate Gilteritinib resistance: Rationale for c-KIT degraders over kinase inhibitors.Acta Pharm Sin B2026https://conductscience.org/library/papers/42368576PubMed
42365365Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.J Hematol Oncol2026https://conductscience.org/library/papers/42365365PubMed
42338241Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation.Immunology2026https://conductscience.org/library/papers/42338241PubMed
42323414SGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemia.NPJ Precis Oncol2026https://conductscience.org/library/papers/42323414PubMed
42291184ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance.iScience2026https://conductscience.org/library/papers/42291184PubMed
42265394Conception-calibrated male pediatric tumor mitotic clocks.Commun Biol2026https://conductscience.org/library/papers/42265394PubMed
42255490Integrative Analysis of Genetic Risk Factors for Acute Myeloid Leukemia Using Mendelian Randomization and Single-Cell RNA Sequencing Validation.Int J Genomics2026https://conductscience.org/library/papers/42255490PubMed
42211128LDLRAD2 drives glycolysis and angiogenesis to promote extramedullary infiltration in acute myeloid leukemia.iScience2026https://conductscience.org/library/papers/42211128PubMed
42192458Heat shock protein 60-targeted peptide-conjugated platinum nanozyme: redox regulation by multi-enzyme activities induces mitochondrial reprogramming and acute leukemia cells fate switch.J Nanobiotechnology2026https://conductscience.org/library/papers/42192458PubMed

See all 95 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39300079

GET https://conductscience.org/api/papers/v1/39300079/references?page=2